London, UK: Daily use of cannabidiol reduces the severity of symptoms in patients at high risk of developing clinical psychosis, according to data from a placebo-controlled clinical trial published in the journal World Psychiatry.
31 patients completed the study. Subjects took 600mg of CBD or a placebo daily for three weeks. No participants received prescription drugs during the study. Patients were evaluated at baseline, day 7, and day 21.
Compared to the placebo group, patients who received CBD had lower CAARMS (Comprehensive Assessment of Risk Mental Status) total scores after treatment. The researchers reported that CBD administration was associated with “reductions in CHR (clinically high risk) symptom severity and distress associated with psychotic experiences.”
The authors of this study concluded: “Short-term treatment with CBD can improve the symptoms of psychotic CHR conditions and is well tolerated. These results support the potential of CBD as a new treatment for psychosis and its clinical utility. This highlights the need for larger efficacy studies for further evaluation.”
Another study demonstrated that CBD use reduced psychotic symptoms and antipsychotic medication use in patients with schizophrenia.
The full text of the study, “Effects of cannabidiol on symptoms in people in clinical settings. High risk of psychosis,” was published in World Psychiatry.
Something like this:
Like loading…
